Patents Assigned to Allergan
  • TREATMENT OF SUBMENTAL FAT
    Publication number: 20220387449
    Abstract: This disclosure relates to compositions, kits and methods for non-surgical reduction of localized subcutaneous fat such as that associated with a cosmetic fat accumulation. The methods employ compositions having specific concentrations of a salt of deoxycholic acid which provides a superior fat cell necrosis with modest adverse effects. Examples of localized subcutaneous fat are found in the submental area, in particular under the chin.
    Type: Application
    Filed: May 24, 2022
    Publication date: December 8, 2022
    Applicant: Allergan Sales, LLC
    Inventor: Patricia Walker
  • TOPICAL COMPOSITION AND METHOD OF USE
    Publication number: 20220387284
    Abstract: The present invention relates to a topical composition that can be used to treat skin laxity, cellulite and to firm, smooth and/or tone skin.
    Type: Application
    Filed: May 25, 2022
    Publication date: December 8, 2022
    Applicant: ALLERGAN SALES, LLC
    Inventors: Patrick Nido, Kuniko Kadoya, Prithwiraj Maitra, Rahul Mehta, Elizabeth Makino
  • Process and system for obtaining botulinum neurotoxin
    Patent number: 11518986
    Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
    Type: Grant
    Filed: March 15, 2022
    Date of Patent: December 6, 2022
    Assignee: Allergan, Inc.
    Inventors: Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
  • Lighter weight implant
    Patent number: 11497598
    Abstract: A breast implant is provided which includes a filling, or core having a lower overall density relative to silicone gel-filled or saline-filled implant. The core may be a composite including flexible bodies, for example, air-containing or gas-containing bodies, and a gel medium between or around the bodies.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: November 15, 2022
    Assignee: Allergan, Inc.
    Inventor: David Schuessler
  • Opioid receptor modulator dosage formulations
    Patent number: 11484527
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: December 8, 2021
    Date of Patent: November 1, 2022
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Poly-Dioxanone Multi-Block Copolymer for Ocular Protein Delivery
    Publication number: 20220331258
    Abstract: Provided herein are poly(ether ester) multi-block copolymers (PEE-MBCP). Also provided herein are injectable delivery systems or pharmaceutical compositions, comprising a PEE-MBCP provided herein, either alone or in combination with a binding protein, such as abicipar. Also provided herein are methods of using these injectable delivery systems or pharmaceutical compositions provided herein for the treatment of ocular disorders.
    Type: Application
    Filed: September 30, 2020
    Publication date: October 20, 2022
    Applicant: Allergan Sales, LLC
    Inventors: Patrick Hughes, Hongwen Rivers, Jie Shen, Johan Zuidema, Henk Haitjema, Christine Hiemstra, Rob Steendam
  • Animal protein-free pharmaceutical compositions
    Patent number: 11446382
    Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: September 20, 2022
    Assignee: Allergan, Inc.
    Inventor: Terrence J. Hunt
  • TOPICAL COMPOSITION AND METHOD OF USE
    Publication number: 20220218584
    Abstract: The present invention relates to a topical composition that can be used to treat skin aging of the neck and décolletage area.
    Type: Application
    Filed: January 13, 2022
    Publication date: July 14, 2022
    Applicant: ALLERGAN SALES, LLC
    Inventors: Patrick Nido, Kuniko Kadoya, Prithwiraj Maitra, Rahul Mehta, Elizabeth Makino
  • Treatment of submental fat
    Patent number: 11344561
    Abstract: This disclosure relates to compositions, kits and methods for non-surgical reduction of localized subcutaneous fat such as that associated with a cosmetic fat accumulation. The methods employ compositions having specific concentrations of a salt of deoxycholic acid which provides a superior fat cell necrosis with modest adverse effects. Examples of localized subcutaneous fat are found in the submental area, in particular under the chin.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: May 31, 2022
    Assignee: Allergan Sales, LLC
    Inventor: Patricia Walker
  • INJECTABLE HOMOGENEOUS GELS COMPRISING MULTIPLE FORMS OF HYALURONIC ACID AND METHODS FOR MANUFACTURING THEREOF
    Publication number: 20220160934
    Abstract: Provided herein are compositions, comprising hyaluronic acid in three different forms. The compositions are in a form of an essentially homogeneous gel with improved rheological properties enabling improved clinical performance.
    Type: Application
    Filed: March 23, 2020
    Publication date: May 26, 2022
    Applicant: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
    Inventors: David Dadi SEGAL, Liat GOLDSHAID-ZMIRI, Lital SHKLANOVSKY, Eran GOLDBERG
  • Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
    Patent number: 11331306
    Abstract: The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, (S) 4-[1-(2,3-dimethylphenylpethyl]-1H-imidazole or (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: May 17, 2022
    Assignee: ALLERGAN, INC.
    Inventors: Mohammed I. Dibas, John E. Donello, Daniel W. Gil
  • Immuno-based botulinum toxin serotype A activity assays
    Patent number: 11332518
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: May 17, 2022
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton E. Garay, Lina Wong, D. Dianne Hodges, Kei Roger Aoki
  • Process and system for obtaining botulinum neurotoxin
    Patent number: 11326155
    Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
    Type: Grant
    Filed: October 19, 2021
    Date of Patent: May 10, 2022
    Assignee: Allergan, Inc.
    Inventors: Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
  • Opioid receptor modulator dosage formulations
    Patent number: 11311516
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: September 22, 2021
    Date of Patent: April 26, 2022
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • FORMULATIONS AND METHODS FOR PROVIDING PROGESTIN-ONLY CONTRACEPTION
    Publication number: 20220117977
    Abstract: Formulations and methods for providing progestin-only contraception to a woman including transdermally administering to a woman a formulation having a contraceptively effective amount of progestin-only hormonal agents as part of a contraceptive regimen.
    Type: Application
    Filed: December 29, 2021
    Publication date: April 21, 2022
    Applicant: ALLERGAN SALES, LLC
    Inventors: Charles Ebert, Gary Hoel, Angela Anigbogu, Samir Roy
  • Phenyl urea derivatives as N-formyl peptide receptor modulators
    Patent number: 11286234
    Abstract: The present invention relates to phenyl urea derivatives useful for the treatment of inflammatory diseases, pharmaceutical compositions containing them and their use as tools or as pharmaceuticals as modulators of the N-formyl peptide receptor (FPR), including FPR1 and FPR2, or as selective agonists of the FPR1 receptor.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: March 29, 2022
    Assignee: Allergan, Inc.
    Inventors: Tien T. Duong, Richard L. Beard, Michael E. Garst
  • Presbyopia treatments
    Patent number: 11285134
    Abstract: Described herein are methods and compositions for the treatment of ocular conditions and for the improvement of vision parameters using pharmaceutically acceptable ophthalmic pilocarpine formulations. A nonlimiting example of an ocular condition that may be treated with the methods and compositions disclosed herein is presbyopia.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: March 29, 2022
    Assignee: ALLERGAN, INC.
    Inventors: Michael R. Robinson, Mohammed Dibas, Jaya Giyanani, Anuradha Gore, Sungwook Lee, Haixia Liu, Aileen Morgan, Jihao Zhou
  • Animal protein-free pharmaceutical compositions
    Patent number: 11285216
    Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: March 29, 2022
    Assignee: Allergan, Inc.
    Inventor: Terrence J. Hunt
  • TREATMENTS OF ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND SALTS THEREOF
    Publication number: 20220072011
    Abstract: Provided herein are methods of treating a variety of disorders related to fat accumulation in humans with pharmaceutical formulations containing deoxycholic acid.
    Type: Application
    Filed: April 30, 2021
    Publication date: March 10, 2022
    Applicant: Allergan Sales, LLC
    Inventors: Frederick Beddingfield, Elisabeth Sandoval, Nancy Jorgesen, Serge Lichtsteiner, Paul Lizzul, Todd Gross, Christine Somogyi
  • Immuno-based botulinum toxin serotype A activity assays
    Patent number: 11261240
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: March 1, 2022
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton E. Garay, Lina Wong, D. Diane Hodges, Kei Roger Aoki